Clinical trials: Gastroparesis
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Gastroparesis
Different Doses of Naronapride vs. Placebo in Gastroparesis
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to…
- Trial name
- MOVE-IT (NCT05621811)
- Testing
- Naronapride
- Where
- 24 sites in United States, Belgium
- Volunteers
- 328 people
- Sponsor
- Dr. Falk Pharma GmbH
Idiopathic Gastroparesis, Diabetic Gastroparesis
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Conditions
- Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
- Trial name
- NCT04028492
- Testing
- Tradipitant, Open Label Tradipitant
- Where
- 36 sites in United States
- Volunteers
- 979 people
- Sponsor
- Vanda Pharmaceuticals
Gastroparesis
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis.
- Trial name
- NCT04026997
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- CinDome Pharma, Inc.
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.
- Trial name
- NCT04303195
- Testing
- NG101
- Where
- 83 sites in United States
- Volunteers
- 161 people
- Sponsor
- Neurogastrx, Inc.
Gastroparesis
Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers
The Vibrant capsule is a novel vibrating device for the treatment of gastrointestinal disorders. The effect of different vibrations on the motor functions of the gastrointestinal tract are unclear.
- Trial name
- NCT02736799
- Testing
- Vibrant Capsule (1 vibration), Vibrant Capsule (3 vibration), Vibrant Capsule (5 vibration)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vibrant Ltd.
Gastroparesis
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will…
- Trial name
- NCT02970968
- Testing
- VLY-686 (Tradipitant)
- Where
- 38 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vanda Pharmaceuticals
Diabetic Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
- Trial name
- NCT03544229
- Testing
- TAK-906 Maleate
- Where
- 109 sites in United States, Belgium and 2 more
- Volunteers
- 242 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastroparesis
A Study of CNSA-001 in Women With Diabetic Gastroparesis
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or…
- Trial name
- NCT03712124
- Testing
- CNSA-001
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- PTC Therapeutics
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo…
- Trial name
- NCT03420781
- Testing
- Relamorelin
- Where
- 337 sites in United States, Argentina and 24 more
- Volunteers
- 467 people
- Sponsor
- Allergan
Gastroparesis
Diabetic Gastroparesis Study 05
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 [NCT03420781] or RLM-MD-04 [NCT03383146] study and to provide treatment for these…
- Trial name
- NCT03786380
- Testing
- Relamorelin 10 μg
- Where
- 486 sites in United States, Argentina and 28 more
- Volunteers
- 202 people
- Sponsor
- Allergan
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.
- Trial name
- NCT03383146
- Testing
- Relamorelin
- Where
- 349 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Allergan
Gastroparesis
GEBT Telehealth Administration Usability Study
The purpose of this study is to establish the usability of a telehealth platform for the administration of GEBT.
- Trial name
- NCT04684992
- Testing
- GEBT Telehealth Administration Usability
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cairn Diagnostics
Diabetic Gastroparesis
A Scintigraphy Study in Adults With Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
- Trial name
- NCT04208698
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis, Diabetes Mellitus
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03426345
- Testing
- Relamorelin
- Where
- 240 sites in United States, Argentina and 13 more
- Volunteers
- 311 people
- Sponsor
- Allergan
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03285308
- Testing
- Relamorelin
- Where
- 216 sites in United States, Australia and 12 more
- Volunteers
- 336 people
- Sponsor
- Allergan
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Diabetic Gastroparesis, Idiopathic Gastroparesis
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
- Trial name
- NCT03281577
- Testing
- TAK-954
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
- Trial name
- NCT03268941
- Testing
- TAK-906 Maleate, Metaclopramide
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.
- Trial name
- NCT02025725
- Testing
- Metoclopramide Nasal Spray
- Where
- 50 sites in United States
- Volunteers
- 205 people
- Sponsor
- Evoke Pharma